21 CFR 1271.155
Exemptions and alternatives
21 CFR 1271.155 is the regulation titled “Exemptions and alternatives” in 21 CFR Part 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products. Since 2021, 12 FDA warning letters have cited it.
- Letters citing it
- 12 since 2021
- Jan 1 to Oct 30, 2026
- 3 against 2 on the same dates in 2025
- Most often cited with
- 21 CFR 1271.60, in 12 letters
- Closed out
- 8% of these letters have a published close-out
Letters citing it, by year issued
All are biologics letters. 2026 runs to Oct 30, 2026. Pick a year to see its letters.
The regulation
Read the text of 21 CFR 1271.155 (eCFR, as of Sep 1, 2026)
(a) General. You may request an exemption from or alternative to any requirement in subpart C or D of this part.
(b) Request for exemption or alternative. Submit your request under this section to the Director of the appropriate Center (the Director), e.g., the Center for Biologics Evaluation and Research or the Center for Devices and Radiological Health. The request must be accompanied by supporting documentation, including all relevant valid scientific data, and must contain either:
(1) Information justifying the requested exemption from the requirement, or
(2) A description of a proposed alternative method of meeting the requirement.
(c) Criteria for granting an exemption or alternative. The Director may grant an exemption or alternative if he or she finds that such action is consistent with the goals of protecting the public health and/or preventing the introduction, transmission, or spread of communicable diseases and that:
(1) The information submitted justifies an exemption; or
(2) The proposed alternative satisfies the purpose of the requirement.
(d) Form of request. You must ordinarily make your request for an exemption or alternative in writing (hard copy or electronically). However, if circumstances make it difficult (e.g., there is inadequate time) to submit your request in writing, you may make the request orally, and the Director may orally grant an exemption or alternative. You must follow your oral request with an immediate written request, to which the Director will respond in writing.
(e) Operation under exemption or alternative. You must not begin operating under the terms of a requested exemption or alternative until the exemption or alternative has been granted. You may apply for an extension of an exemption or alternative beyond its expiration date, if any.
(f) Documentation. If you operate under the terms of an exemption or alternative, you must maintain documentation of:
(1) FDA's grant of the exemption or alternative, and
(2) The date on which you began operating under the terms of the exemption or alternative.
(g) Issuance of an exemption or alternative by the Director. In a public health emergency, the Director may issue an exemption from, or alternative to, any requirement in part 1271. The Director may issue an exemption or alternative under this section if the exemption or alternative is necessary to assure that certain HCT/Ps will be available in a specified location to respond to an unanticipated immediate need for those HCT/Ps.
Text from eCFR as of Sep 1, 2026.
Cited alongside it
Regulations that appear in the same letters as 21 CFR 1271.155.
- 21 CFR 1271.60What quarantine and other requirements apply before the donor-eligibility determination is complete?12 letters cite both
- 21 CFR 1271.75How do I screen a donor?12 letters cite both
- 21 CFR 1271.90Are there other exceptions and what labeling requirements apply?12 letters cite both
- 21 CFR 1271.85What donor testing is required for different types of cells and tissues?11 letters cite both
- 21 CFR 1271.80What are the general requirements for donor testing?10 letters cite both
- 21 CFR 1271.3How does FDA define important terms in this part?9 letters cite both
- 21 CFR 1271.45What requirements does this subpart contain?9 letters cite both
- 21 CFR 1271.47What procedures must I establish and maintain?9 letters cite both
Latest letters citing it
The 3 letters citing 21 CFR 1271.155 that FDA posted most recently.
- BiologicsView Central Coast Multispecialty Medical Group, Inc.human cells, tissues, and cellular and tissue-based products (HCT/Ps)IssuedJan 29, 2026PostedFeb 10, 2026
- BiologicsView Conceive Fertility Centerreproductive cells or tissue (oocytes and semen)IssuedJan 27, 2026PostedFeb 10, 2026
- BiologicsView Louisville Reproductive Centerreproductive cells and tissue (semen, oocytes, embryos)IssuedJan 23, 2026PostedFeb 10, 2026
Put this kind of reading to
work on your own records.
Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.
Counts include every citation in a letter, as the Letters filter does. How this database is built.